This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.

Fiorentino M, Giunchi F, Altimari A, Di Tullio P, Gruppioni E, Martorana G, et al. (2014). Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations. THE ONCOLOGIST, 19(40), 430-430 [10.1634/theoncologist.2013-0346].

Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations

FIORENTINO, MICHELANGELO;
2014

Abstract

This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.
2014
Fiorentino M, Giunchi F, Altimari A, Di Tullio P, Gruppioni E, Martorana G, et al. (2014). Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations. THE ONCOLOGIST, 19(40), 430-430 [10.1634/theoncologist.2013-0346].
Fiorentino M; Giunchi F; Altimari A; Di Tullio P; Gruppioni E; Martorana G; Pinto C.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/577865
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact